NCT00505973View on ClinicalTrials.gov

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2007

Study Completion Date

October 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

SCA-136

Trial Locations (1)

171-0014

Ikebukuro

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00505973 - Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects | Biotech Hunter | Biotech Hunter